APLIF (Appili Therapeutics) Scaled Net Operating Assets: -5.50 (As of Dec. 2025)


What is Appili Therapeutics Scaled Net Operating Assets?

Appili Therapeutics APLIF Scaled Net Operating Assets is -5.50 as of Dec. 2025. The stock has 4 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Appili Therapeutics's operating assets for the quarter that ended in Dec. 2025 was $0.24 Mil. Appili Therapeutics's operating liabilities for the quarter that ended in Dec. 2025 was $3.24 Mil. Appili Therapeutics's Total Assets for the quarter that ended in Sep. 2025 was $0.55 Mil. Therefore, Appili Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was -5.50.

Appili Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Appili Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Appili Therapeutics Scaled Net Operating Assets Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Scaled Net Operating Assets
Get a 7-Day Free Trial -0.23 -0.27 -0.25 -0.92 -1.47

Appili Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.55 -1.10 -1.18 -1.94 -5.50

APLIF vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Appili Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Appili Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's Scaled Net Operating Assets falls into.


Appili Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Appili Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2025 )
=(Operating Assets (A: Mar. 2025 )-Operating Liabilities (A: Mar. 2025 ))/Total Assets (A: Mar. 2024 )
=(1.258-2.881)/1.101
=-1.47

where

Operating Assets(A: Mar. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2.113 - 0.855
=1.258

Operating Liabilities(A: Mar. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=11.445 - 0.513 - 8.051
=2.881

Appili Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Sep. 2025 )
=(0.243-3.242)/0.545
=-5.50

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.397 - 0.154
=0.243

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=12.275 - 0.534 - 8.499
=3.242

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -5.50 mean?
Appili Therapeutics (APLIF) has a Scaled Net Operating Assets of -5.50 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Appili Therapeutics and its competitors.
Is Appili Therapeutics' Scaled Net Operating Assets too high?
Appili Therapeutics' current Scaled Net Operating Assets is -5.50.
How does Appili Therapeutics' Scaled Net Operating Assets compare to VRTX and REGN?
Appili Therapeutics' Scaled Net Operating Assets of -5.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Appili Therapeutics and its competitors. Appili Therapeutics's current Scaled Net Operating Assets is -5.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (APLIF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 13% above its estimated fair value. The current Scaled Net Operating Assets is -5.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Appili Therapeutics (APLIF), the current Scaled Net Operating Assets is -5.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Appili Therapeutics Business Description

Other Exchanges APLI:Canada
Address 1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.